The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC

HONG KONG, Aug. 7, 2023 /PRNewswire/ — Akeso Inc. (“Akeso”, the “Company”; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that eClinical Medicine(IF:15.1), a…